58 results about "Lipoteichoic acid" patented technology

The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.

The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophthalmological applications, a food or petfood composition for modulating bacterial colonisation, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof.

The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally.

PCT No. PCT/EP96/00309 Sec. 371 Date Oct. 28, 1997 Sec. 102(e) Date Oct. 28, 1997 PCT Filed Jan. 24, 1996 PCT Pub. No. WO96/23896 PCT Pub. Date Aug. 8, 1996A new bacteria species within the genus Streptococcus is disclosed, designated as Streptococcus sp PT DSM 8747. From this bacteria species a lipoteichoic acid LTA can be isolated which has a lipid anchor, galacto-furanosyl-beta-1-3-glycerol with different rests of fatty acids esterified to the two adjacent hydroxy groups in the glycerol moiety and a non-glycosylated, linear, unbranched GroP chain. The hydrophilic backbone may comprise 10 glycerophosphate units esterified with D-alanine in an extent of about 30%. The invention further concerns a pharmaceutical composition with the LTA, optionally together with a monokine and/or hyaluronidase, a method of treating cancer comprising administrating an antitumor effective amount thereof, a method of producing the LTA, and degradation products of the LTA and their use.

The invention provides a production process of a soy sauce flavor type soybean sauce. The soy sauce flavor type soybean sauce is prepared by using vinasse as a raw material, and aspergillus oryzae strains and bifidobacterium strains as strains. The production process is characterized in that with vinasse as the raw material, the production cost is reduced; and meanwhile, with bifidobacterium as a fermenting strain, the prepared soybean sauce contains nutritional ingredients such as lipoteichoic acid, membrane teichoic acid and peptidoglycan, so that the soybean sauce is endowed with a unique flavor, and the soybean sauce has the efficacies of enhancing the immunologic function and anti-tumour effect of the organism, relieving and removing fatigue, adjusting balance of intestinal microflora and improving the liver function, has nutritional benefits, and also has the efficacies of relieving uremia, resisting anaphylaxis, increasing the appetite, reducing blood pressure and blood cholesterol, preventing arteriosclerosis and the like, so as to promote health of a human body. The soybean sauce prepared by the production process is dark in color, and thick in juice, contains sugar but is not sweet, contains salt but is not salty, contains acid but is not sour, and has the unique thick soy sauce flavor.

Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneuomococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of either neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid. Optionally, the composition can comprise any combination of a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these. Optionally the agents are detoxified. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein. Also provided are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to the subject a composition taught herein.

The present invention relates to a group of peptidic compounds which have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. These compounds can inhibit or neutralize the toxins. In addition, the present invention relates to the use of these compounds as therapeutic or diagnostic agents.

The invention provides a soy sauce flavor type vinegar making process. Distillers' grains are utilized as the raw material to make the soy sauce flavor type vinegar, so that raw material cost is reduced, meanwhile a raw material alcoholic fermentation step is reduced, and the made vinegar has soy sauce flavor. Acetic acid strain and bifidobacterium strain are utilized as the vinegar making fermentation strain, and the made vinegar contains nutrient contents such as lactic acid, acetic acid, multivitamin, lipoteichoic acid, teichoic acid and peptidoglycan by means of control of temperature, oxygen and the like of all fermentation periods. The vinegar not only has the specific flavor of itself but also achieves the effects of enhancing the immunity of a human body, restraining cancer, remitting and removing fatigue, adjusting the balance of enteric microbial flora, improving the liver function, improving the nutrition effect, remitting the uremia, resisting allergy, increasing appetite, reducing blood pressure and cholesterol in blood, preventing arteriosclerosis and the like, so that the vinegar can further promote human body health, enhances national physical health and has good social and economical benefits. Therefore, the bifidobacterium vinegar is the modern novel healthcare vinegar which can enhance human body health and is cheap and fine.

The invention discloses a lipoteichoic acid from clostridium butyricum and an application thereof in adjusting an immune response of livestock and poultry. The lipoteichoic acid is obtained by the steps of firstly preparing a TX-114 solution with a mass percentage of 1.5-2.5% for use; then layering 8-16 mL of a clostridium butyricum solution cultured for 45-50 h by centrifugation to obtain wet weight of clostridium butyricum; adding the TX-114 solution; centrifuging to obtain a crude extract of lipoteichoic acid; and then separating through column chromatography on a DEAE-cellulose chromatographic column. The lipoteichoic acid can improve intestinal immune functions of the livestock and poultry, suppress adhesion and attachment of pathogenic bacteria on surfaces of intestinal mucosal cells, reduce incidence of intestinal infectious diseases and increase economic benefits of livestock and poultry industry.

The invention discloses an application of lipoteichoic acid from clostridium butyricum in adjusting an immune response of aquatic livestock. The lipoteichoic acid is from clostridium butyricum and is different from cell wall lipoteichoic acid structures of other gram-positive bacteria. The lipoteichoic acid can improve intestinal immune functions of the aquatic livestock, suppress infections of pathogenic bacteria to the aquatic livestock and reduce incidence of diseases.

Methods for reducing or inhibiting polyposis or colorectal cancer are provided. The methods comprise administering to a mammal a bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods find use in treating or preventing a variety of polyp-related disorders, for example, treating or Lynch syndrome, familial adenomatous polyposis, and colorectal cancer.

The invention relates to a metagen and a preparation method and application thereof, the metagen comprises inactivated lactobacillus plantarum LP220 and a fermentation metabolite thereof, and the preservation number of the lactobacillus plantarum LP220 is CCTCC (China Center For Type Culture Collection) NO: M2018465. The metagen comprises the following components: lactobacillus plantarum LP220 greater than or equal to 1 * 10 < 11 > CFU/g, lipoteichoic acid greater than or equal to 35 ng/kg, short-chain fatty acid greater than or equal to 90 [mu] g/g, polypeptide content greater than or equal to 6%, and molecular weight 1t; 1000DA small molecule peptide accounts for more than 80% of the total peptide content, and the organic acid content is more than or equal to 100mg/g. The invention further discloses a preparation method of the postbiotics and application of the postbiotics in preparation of dietary supplements, health care products, medicines, foods or solid beverages for enhancing immunity. The metagen contains lactobacillus plantarum thalli above 1 * 10 < 11 > CFU/g, is rich in functional components such as small molecule peptides, short-chain fatty acids, organic acids, amino acids and the like, and improves and regulates the organ index, cellular immune function and NK cell activity of a body to remarkably enhance the immune function of the body.

The invention relates to preparation of lipoteichoic acid monoclonal antibodies and an e-linked immunosorbent assay (ELISA) detection kit manufactured by using the preparation. An ELISA detection reagent is a high-technology product in the field of biological medicines, and is an in-vitro diagnostic reagent. Following a search, the ELISA detection reagent fills the domestic blank, the current situation of detecting staphylococcus aureus by using a time-wasting and labor-wasting blood culture method is changed, an enzyme linked immunosorbent assay which is high in sensitivity and specificity is adopted, and detection time is shortened. Balb/c female mice are immuned by lipoteichoic acid antigens extracted from cell walls of the staphylococcus aureus, then monoclonal antibodies L are obtained and are IgG immune globulin after being detected, and the valence of the antibodies is 1*106. The monoclonal antibodies are purified by a saturated ammonium sulfate precipitation and affinity chromatography technology. Lipoteichoic acids serve as coating antigens, the obtained monoclonal antibodies serve as enzyme-labeled antibodies, and then a competition-method ELISA kit is manufactured and is used for diagnosing staphylococcus aureus infection which serves as one of references for clinical diagnosis.

This invention is directed to compositions and methods for treating (e.g., prophylactically and/or therapeutically) infection in a preterm infant. In particular, the invention provides anti-lipoteichoic acid (LTA) antibody compositions and methods of administering the same to a preterm infant (e.g., a low birth weight preterm infant (e.g., a very low birth weight preterm infant)) under conditions to establish anti-LTA antibody serum concentrations effective to kill and/or prevent growth of bacteria (e.g., Staphylococci). Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine) and research applications.

The invention provides a shampoo for treating seborrheic dermatitis, and belongs to the technical field of daily chemical products. The shampoo comprises a shampoo composition comprising a common bombax flower extract, a tea oil cake extract, monohydroxyethyl rutin and L-cysteic acid, a flaxseed extract and rice extract. The invention also provides a shampoo for repairing scalp damage and a methodof using the same. The shampoo for treating seborrheic dermatitis can promote staphylococcus epidermidis to secrete lipoteichoic acid, inhibiting phosphorylation induction of malassezia furfur to P65protein in the keratinocyte NF-kB pathways; the expression of partial glyceride lipase of malassezia globosa is inhibited to suppress the growth of the malassezia globosa, thereby alleviating the inflammatory response of the scalp and improving the treatment effect on the scalp seborrheic dermatitis.

The invention discloses an immunogenic polypeptide capable of simulating staphylococcus aureus LTA epitopes and application of the immunogenic polypeptide. A core amino acid sequence of the polypeptide is VHWDFRQWWQPS or GHWDFRQWWQPS. The polypeptide has the advantages that the polypeptide is good in antigenicity and capable of specifically binding with monoclonal antibodies targeting at lipoteichoic acids of multiple kinds of gram-positive bacteria, thereby being capable of well simulating conserved epitopes of the lipoteichoic acids; immunogen immunized mice synthesized by the polypeptide can be induced to resist systemic infection of Staphylococcus aureus and is hopefully developed into a novel protective vaccine and a diagnostic reagent of the Staphylococcus aureus.

Tetrapeptides consisting of (I or V)-X1-K-X2, where X1 can be selected from E, Q or K, and X2 can be selected from M, F, I, W, or V, exhibit diverse bioactivities. They are multi-functional effector molecules to stimulate keratinocytes migration; neutralize the proinflammatory effect of bacterial cell wall components such as lipoteichoic acids of the Gram-positive S. aureus; and induce angiogenesis in cultured human umbilical vein endothelial cells. The downregulation of pro-inflammatory condition was also demonstrated using SOR-300-FT psoriasis skin model for representative peptide. The bioactivity was also supported by gene profiling study upon treatment of normal skin tissues using EPIDERM™ skin substitutes. The inventive peptides with diverse bioactivities are useful for treating various skin conditions including, but not limited to, acute or chronic wounds, striae distensae, aging skin, hair control, inflammatory skins such as psoriasis, atopic dermatitis and rosacea and for unwanted hair removal or for conditions such as removal of skin tags.